All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Corticosteroids are the accepted first-line therapy for chronic graft-versus-host disease (cGvHD), a major complication of hematopoietic stem cell transplantation (HSCT). Nevertheless, 50–60% of these patients develop steroid-refractory GvHD (SR-GvHD), which is associated with poor survival rates. In order to improve patient outcomes, new second-line therapy options are required.
Badri Modi from Department of Surgery, Division of Dermatology, City of Hope, Duarte, CA, USA, and colleagues retrospectively evaluated patients with GvHD treated with ruxolitinib as salvage therapy. The study was published ahead of print in Biology of Blood and Marrow Transplantation.
In summary, the results of this study showed that ruxolitinib salvage therapy demonstrated a superior FFS and ORR at 12 months. It is also encouraging to note that ruxolitinib use led to lower steroid use. The authors stated that “ruxolitinib as salvage therapy is promising for cGvHD refractory to steroids.” The REACH3 phase III multicenter, open-label randomized trial (n = 324 patients) is underway to evaluate ruxolitinib versus best available therapy for patients with SR-GvHD as second line of therapy.
Refined National Institutes of Health response algorithm for joint- and fascia-associated chronic graft-versus-host disease
Establishment of joint-/fascia-associated graft-versus-host disease (GvHD) occurs in 3–24% of patients with chronic GvHD...
Ileostomy for steroid-resistant acute graft-versus-host disease of the gastrointestinal tract
Results from a retrospective study in Annals of Hematology demonstrated that ileostomy induced significant clinical responses in patients with...
Subscribe to get the best content related to GvHD delivered to your inbox